Therapy Areas: Cardiovascular
Dicerna Pharmaceuticals signs contract with Novo Nordisk
20 November 2019 - United States-based Dicerna Pharmaceuticals has signed a contract with Denmark-based Novo Nordisk for discovering and developing drugs for liver-related cardio-metabolic diseases, i...
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
19 November 2019 - - US-based pharmaceutical company Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) and Denmark-based Novo Nordisk A/S have inked an agreement to discover and develop nove...
Consistent Effects of Farxiga in Heart Failure Patients with Reduced Ejection Fraction Shown in New Analyses from Landmark Phase III DAPA-HF Trial
19 November 2019 - - British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) released new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga ...
Subgroup Analysis of TWILIGHT Trial Patients with Non-ST Elevation Acute Coronary Syndrome Who Underwent PCI Showed Brilinta Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared with Dual Antiplatelet Therapy
19 November 2019 - - New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to...
US FDA Approves Pfizer's Biosimilar, Abrilada for Multiple Inflammatory Conditions
19 November 2019 - - The United States Food and Drug Administration has approved US-based pharmaceutical company Pfizer Inc.'s (NYSE: PFE) Abrilada (adalimumab-afzb), as a biosimilar to Humira&nb...
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
15 November 2019 - - US-based clinical stage biopharmaceutical company Aadi Bioscience, Inc has released its independent radiology reviewed data from the nab-sirolimus (ABI-009) registration tria...